Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
SymbolNASDAQ:OMCL
CUSIP68213N10
Phone650-251-6100
Debt
Debt-to-Equity Ratio0.31
Current Ratio1.78
Quick Ratio1.27
Price-To-Earnings
Trailing P/E Ratio347.61
Forward P/E RatioN/A
P/E Growth3.12
Sales & Book Value
Annual Sales$716.16 million
Price / Sales3.43
Cash Flow$1.5761 per share
Price / Cash39.70
Book Value$13.64 per share
Price / Book4.59
Profitability
EPS (Most Recent Fiscal Year)$0.18
Net Income$20.60 million
Net Margins5.27%
Return on Equity5.88%
Return on Assets3.19%
Miscellaneous
Employees2,350
Outstanding Shares39,270,000
Market Cap$2.48 billion
Omnicell (NASDAQ:OMCL) Frequently Asked Questions
What is Omnicell's stock symbol?
Omnicell trades on the NASDAQ under the ticker symbol "OMCL."
How were Omnicell's earnings last quarter?
Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings results on Thursday, July, 26th. The company reported $0.46 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.07. The firm had revenue of $188.70 million for the quarter, compared to the consensus estimate of $188.80 million. Omnicell had a return on equity of 5.88% and a net margin of 5.27%. The business's revenue was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.31 earnings per share. View Omnicell's Earnings History.
When is Omnicell's next earnings date?
How can I listen to Omnicell's earnings call?
Omnicell will be holding an earnings conference call on Thursday, October 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8006965518.
What guidance has Omnicell issued on next quarter's earnings?
Omnicell updated its FY18 earnings guidance on Thursday, July, 26th. The company provided EPS guidance of $1.90-2.05 for the period, compared to the Thomson Reuters consensus estimate of $1.95. The company issued revenue guidance of $780-800 million, compared to the consensus revenue estimate of $791.02 million.Omnicell also updated its Q3 guidance to $0.52-0.57 EPS.
What price target have analysts set for OMCL?
6 analysts have issued twelve-month target prices for Omnicell's shares. Their forecasts range from $55.00 to $80.00. On average, they anticipate Omnicell's share price to reach $67.1667 in the next twelve months. This suggests a possible upside of 8.2% from the stock's current price. View Analyst Price Targets for Omnicell.
What is the consensus analysts' recommendation for Omnicell?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omnicell.
What are Wall Street analysts saying about Omnicell stock?
Here are some recent quotes from research analysts about Omnicell stock:
- 1. According to Zacks Investment Research, "While, Omnicell’s second-quarter 2018 performance was impressive with both earnings and revenues remaining ahead of the Zacks Consensus Estimate, the dull show within its medication adherence business impacted by unfavorable timing of large robot sales, raises concern. This apart, increasing operating expenses are putting pressure on the bottom line for Omnicell. A resilient hospital capital expenditure environment might adversely affect the adoption of the company’s solutions. Tough competitive landscape also acts as a dampener. On a positive note, we are encouraged to note that the company is working on product innovation through R&D. Also, Omnicell is expected to gain from recent launches, strategic partnerships and digital transformation. Its recent product launches include the XR2 pharmacy robot and the IVX Workflow. Over the past three months, Omnicell’s shares have been outperforming the industry." (8/13/2018)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating on OMCL shares and our 12-month price target remains at $63. After the close on Thursday, July 26, OMCL reported 2Q18 results. Revenue was slightly above our estimates and in line with FactSet consensus. Non-GAAP EPS was well above expectations. The company reiterated its view that it expects long-term organic growth of about 10-12%. The company raised its 2018 bookings guidance slightly (suggesting 14% y/y growth at the midpoint) and raised the low end of its adjusted EPS guidance range. Notable contracts in the quarter included Brigham & Women’s. We maintain our view that OMCL is poised to benefit from significant investments in its products and services." (7/26/2018)
Who are some of Omnicell's key competitors?
Who are Omnicell's key executives?
Omnicell's management team includes the folowing people:
- Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 61)
- Mr. Peter J. Kuipers, Exec. VP & CFO (Age 46)
- Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 54)
- Mr. Robin G. Seim, Pres of Global Automation & Medication Adherence (Age 58)
- Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 58)
Who are Omnicell's major shareholders?
Omnicell's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Copper Rock Capital Partners LLC (1.15%), Tributary Capital Management LLC (0.52%), Scout Investments Inc. (0.39%), West Coast Financial LLC (0.29%), Rhenman & Partners Asset Management AB (0.26%) and Strs Ohio (0.14%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Institutional Ownership Trends for Omnicell.
Which institutional investors are selling Omnicell stock?
OMCL stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Peregrine Capital Management LLC, Strs Ohio, Scout Investments Inc., Rhenman & Partners Asset Management AB, Sumitomo Mitsui Asset Management Company LTD and Juncture Wealth Strategies LLC. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, James T Judson, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Robin Gene Seim. View Insider Buying and Selling for Omnicell.
Which institutional investors are buying Omnicell stock?
OMCL stock was bought by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, West Coast Financial LLC and Everence Capital Management Inc.. View Insider Buying and Selling for Omnicell.
How do I buy shares of Omnicell?
Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Omnicell's stock price today?
One share of OMCL stock can currently be purchased for approximately $62.08.
How big of a company is Omnicell?
Omnicell has a market capitalization of $2.48 billion and generates $716.16 million in revenue each year. The company earns $20.60 million in net income (profit) each year or $0.18 on an earnings per share basis. Omnicell employs 2,350 workers across the globe.
What is Omnicell's official website?
How can I contact Omnicell?
Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]
MarketBeat Community Rating for Omnicell (NASDAQ OMCL)
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.
